It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Using sentiment indicators with index level data combines psychology and price to strengthen analysis. This overview provides steps to integrate both streams.
26,603 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A little-known corner of the market, rare earth stocks have moved in big swings. Here's how USA Rare Earth powered an...
Taiwan Semiconductor is in the spotlight as it signals higher capital spending. This article breaks down whether tsmc...
A fresh budget analysis casts doubt on solvency for Social Security and Medicare, even as Trump reiterates promises t...
Pet insurance stocks are among the year's standout performers in the broader insurance space. This review highlights ...
A new class action filed in California claims Kalshi misled traders in a Khamenei leadership prediction market, resul...
CSX stock has surged, but a move to Bank of America’s $46 target hinges on margin expansion and a steadier freight ma...
A small exodus of California's billionaires ahead of a proposed wealth tax could erase billions in expected revenue. ...
Both ServiceNow and Salesforce fell roughly 5% on the latest trading session as AI licensing concerns rattled investo...
A notable stake reduction in NMI Holdings highlights how large investors weigh growth, risk, and value. Here’s what i...
Micron’s latest earnings and bold capex plans intensify the debate over whether the memory giant can achieve a trilli...
The nuclear energy sector is staging a comeback. This article breaks down two top stock ideas, explains why they matt...